CN102459276B - 从纳曲酮制备盐酸纳美芬 - Google Patents

从纳曲酮制备盐酸纳美芬 Download PDF

Info

Publication number
CN102459276B
CN102459276B CN201080033670.3A CN201080033670A CN102459276B CN 102459276 B CN102459276 B CN 102459276B CN 201080033670 A CN201080033670 A CN 201080033670A CN 102459276 B CN102459276 B CN 102459276B
Authority
CN
China
Prior art keywords
mthf
mixture
nalmefene
naltrexone
obtains
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080033670.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN102459276A (zh
Inventor
C·德法维里
M·卡萨林
M·布鲁塞冈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43222172&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102459276(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of CN102459276A publication Critical patent/CN102459276A/zh
Application granted granted Critical
Publication of CN102459276B publication Critical patent/CN102459276B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
CN201080033670.3A 2009-05-25 2010-05-21 从纳曲酮制备盐酸纳美芬 Expired - Fee Related CN102459276B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200900650 2009-05-25
DKPA200900650 2009-05-25
US18102209P 2009-05-26 2009-05-26
US61/181022 2009-05-26
PCT/DK2010/050110 WO2010136039A1 (en) 2009-05-25 2010-05-21 Preparation of nalmefene hydrochloride from naltrexone

Publications (2)

Publication Number Publication Date
CN102459276A CN102459276A (zh) 2012-05-16
CN102459276B true CN102459276B (zh) 2016-09-21

Family

ID=43222172

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080033670.3A Expired - Fee Related CN102459276B (zh) 2009-05-25 2010-05-21 从纳曲酮制备盐酸纳美芬

Country Status (35)

Country Link
US (1) US8598352B2 (enExample)
EP (1) EP2435439B8 (enExample)
JP (1) JP5794980B2 (enExample)
KR (1) KR101716522B1 (enExample)
CN (1) CN102459276B (enExample)
AR (1) AR076891A1 (enExample)
AU (1) AU2010252392B2 (enExample)
BR (1) BRPI1010975B1 (enExample)
CA (1) CA2763093C (enExample)
CL (1) CL2011002974A1 (enExample)
CO (1) CO6470832A2 (enExample)
CR (1) CR20110612A (enExample)
DK (1) DK2435439T3 (enExample)
DO (1) DOP2011000362A (enExample)
EA (1) EA019331B1 (enExample)
ES (1) ES2564006T3 (enExample)
GE (1) GEP20146190B (enExample)
HR (1) HRP20160110T1 (enExample)
HU (1) HUE026892T2 (enExample)
IL (1) IL216422A (enExample)
MA (1) MA33368B1 (enExample)
ME (1) ME02622B (enExample)
MX (1) MX2011012502A (enExample)
MY (1) MY158251A (enExample)
NZ (1) NZ596988A (enExample)
PL (1) PL2435439T3 (enExample)
RS (1) RS54599B1 (enExample)
SG (1) SG176205A1 (enExample)
SI (1) SI2435439T1 (enExample)
SM (1) SMT201600061B (enExample)
TN (1) TN2011000590A1 (enExample)
TW (1) TWI469985B (enExample)
UA (1) UA106752C2 (enExample)
WO (1) WO2010136039A1 (enExample)
ZA (1) ZA201108659B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2802295C (en) 2010-06-11 2016-09-20 Rhodes Technologies Transition metal-catalyzed processes for the preparation of n-allyl compounds and use thereof
HRP20170379T1 (hr) 2010-11-05 2017-05-05 H. Lundbeck A/S Postupak proizvodnje naltreksona
CN103012416B (zh) * 2011-09-28 2015-07-01 辽宁海思科制药有限公司 一种盐酸纳美芬的制备方法
TWI560170B (en) * 2011-12-06 2016-12-01 Lundbeck & Co As H Process for recovery of nalmefene hydrochloride
CN102584840A (zh) * 2011-12-28 2012-07-18 南京优科生物医药有限公司 一种制备纳美芬化合物的方法
WO2013164383A1 (en) 2012-05-03 2013-11-07 H. Lundbeck A/S Method for the manufacturing of naltrexone
US20140005216A1 (en) 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations
CN103204859B (zh) * 2013-04-25 2015-12-02 四川海思科制药有限公司 一种盐酸纳美芬化合物及其制备方法
AR096851A1 (es) 2013-07-11 2016-02-03 H Lundbeck As Sales que no forman hidratos ni solvatos de nalmefeno
JP6448645B2 (ja) 2013-12-20 2019-01-09 ハー・ルンドベック・アクチエゼルスカベット メランコリアの特徴を伴う抑うつ障害を処置するための、カッパ−活性を伴うオピオイド受容体拮抗薬およびボルチオキセチンの使用
SG10201809280PA (en) 2014-04-22 2018-11-29 Otsuka Pharma Co Ltd Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
CN104513251A (zh) * 2014-11-28 2015-04-15 安徽悦康凯悦制药有限公司 一种盐酸纳美芬的制备方法
US9757372B2 (en) * 2015-03-25 2017-09-12 Taiwanj Pharmaceuticals Co., Ltd. Toll-like receptor 4 antagonists and use in autoimmune liver diseases
RU2712232C1 (ru) * 2018-10-05 2020-01-27 Федеральное государственное унитарное предприятие "Научно-исследовательский институт гигиены, профпатологии и экологии человека" Федерального медико-биологического агентства Улучшенный способ получения налмефена из налтрексона
US10927121B1 (en) 2019-12-20 2021-02-23 Southwest Research Institute Technologies for removing residual solvent from nalmefene hydrochloride and producing crystalline nalmefene hydrochloride monohydrate, monosolvate, or crystalline nalmefene hydrochloride dihydrate
CA3196369A1 (en) 2020-11-02 2022-05-05 C. Frederick M. Huntley Process for purifying noroxymorphone
US20240109907A1 (en) 2021-01-28 2024-04-04 Rhodes Technologies Process for crystallizing nalmefene hydrochloride
CN117843650A (zh) * 2023-12-27 2024-04-09 南京海纳医药科技股份有限公司 一种盐酸纳美芬的精制方法
CN117986261B (zh) * 2024-04-02 2024-06-18 成都瑞尔医药科技有限公司 一种盐酸纳美芬母液的回收套用方法
CN119080788A (zh) * 2024-08-19 2024-12-06 南京海鲸药业股份有限公司 一种盐酸纳美芬杂质的去除监控系统及去除方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0039066A2 (en) * 1980-04-28 1981-11-04 E.I. Du Pont De Nemours And Company 17-Substituted 6-desoxy-7,8-dihydro-6-alpha-methylnoroxymorphone narcotic antagonists
US4535157A (en) * 1983-11-01 1985-08-13 Key Pharmaceuticals, Inc. Process for making 6-desoxy-6-methylenenaloxone and 6-desoxy-6-methylenenaltrexone
US4751307A (en) * 1985-01-17 1988-06-14 Mallinckrodt, Inc. Wittig-reaction processes
EP0352025A2 (en) * 1988-07-22 1990-01-24 Baker Cummins Pharmaceuticals, Inc. Use of nalmefene in the treatment of allergic rhinitis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4341764A (en) 1980-03-05 1982-07-27 Cutter Laboratories, Inc. Method of preparing fibronectin and antihemophilic factor
US7687646B2 (en) 2006-03-28 2010-03-30 Azad Pharmaceutical Ingredients, Ag Polymorphic forms of olopatadine hydrochloride and methods for producing olopatadine and salts thereof
GB2447013A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition containing buprenorphone and nalmefene

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0039066A2 (en) * 1980-04-28 1981-11-04 E.I. Du Pont De Nemours And Company 17-Substituted 6-desoxy-7,8-dihydro-6-alpha-methylnoroxymorphone narcotic antagonists
US4535157A (en) * 1983-11-01 1985-08-13 Key Pharmaceuticals, Inc. Process for making 6-desoxy-6-methylenenaloxone and 6-desoxy-6-methylenenaltrexone
US4751307A (en) * 1985-01-17 1988-06-14 Mallinckrodt, Inc. Wittig-reaction processes
EP0352025A2 (en) * 1988-07-22 1990-01-24 Baker Cummins Pharmaceuticals, Inc. Use of nalmefene in the treatment of allergic rhinitis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Solvent Applications of 2-Methyltetrahydrofuran in Organometallic and Biphasic Reactions;David F. Aycock;《Organic Process Research & Development》;20071231;第11卷;156-159 *

Also Published As

Publication number Publication date
SMT201600061B (it) 2016-07-01
CA2763093C (en) 2017-03-07
BRPI1010975B1 (pt) 2021-08-24
KR101716522B1 (ko) 2017-03-14
TWI469985B (zh) 2015-01-21
MA33368B1 (fr) 2012-06-01
MX2011012502A (es) 2011-12-12
UA106752C2 (uk) 2014-10-10
GEP20146190B (en) 2014-11-10
AR076891A1 (es) 2011-07-13
DOP2011000362A (es) 2012-07-15
HUE026892T2 (en) 2016-07-28
JP2012527489A (ja) 2012-11-08
PL2435439T3 (pl) 2016-05-31
TW201043634A (en) 2010-12-16
CO6470832A2 (es) 2012-06-29
IL216422A (en) 2015-06-30
IL216422A0 (en) 2012-02-29
HRP20160110T1 (hr) 2016-03-11
ME02622B (me) 2017-06-20
BRPI1010975A2 (pt) 2015-10-20
EP2435439B8 (en) 2016-05-18
EP2435439A1 (en) 2012-04-04
EA201171461A1 (ru) 2012-05-30
MY158251A (en) 2016-09-30
SG176205A1 (en) 2011-12-29
US8598352B2 (en) 2013-12-03
AU2010252392B2 (en) 2014-10-23
CA2763093A1 (en) 2010-12-02
CN102459276A (zh) 2012-05-16
AU2010252392A1 (en) 2012-01-12
ES2564006T3 (es) 2016-03-17
JP5794980B2 (ja) 2015-10-14
NZ596988A (en) 2013-03-28
KR20120023704A (ko) 2012-03-13
EA019331B1 (ru) 2014-02-28
RS54599B1 (sr) 2016-08-31
CR20110612A (es) 2012-02-22
CL2011002974A1 (es) 2012-04-13
DK2435439T3 (en) 2016-02-29
ZA201108659B (en) 2013-02-27
WO2010136039A1 (en) 2010-12-02
EP2435439B1 (en) 2016-01-06
TN2011000590A1 (en) 2013-05-24
US20120123123A1 (en) 2012-05-17
SI2435439T1 (sl) 2016-06-30

Similar Documents

Publication Publication Date Title
CN102459276B (zh) 从纳曲酮制备盐酸纳美芬
EP2300479B1 (en) Nalmefene hydrochloride dihydrate
JP6215399B2 (ja) ナルトレキソンの製造方法
CN104093721B (zh) 用于回收盐酸纳美芬的方法
JP2019031524A (ja) ナルメフェン塩酸塩二水和物
HK1170728B (en) Preparation of nalmefene hydrochloride from naltrexone
HK1170728A (en) Preparation of nalmefene hydrochloride from naltrexone
KR101837795B1 (ko) 날트렉손의 제조 방법

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1170728

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1170728

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160921

CF01 Termination of patent right due to non-payment of annual fee